ChIP-seq predicted estrogen receptor biding sites in human breast cancer cell line MCF7
The aim of this study was to find estrogen receptor (ER) binding sites of estradiol (E2)-treated and control groups and discuss the roles of ER activation in the tumorigenesis and progression of various human cancers. The ER ChIP-seq data GSE19013 was downloaded from Gene Expression Omnibus database, including E2-treated data GSM470419 and control data GSM470418. MACS software was utilized to identify ER binding sites in two groups. R’s ChIPpeakAnno was used to detect ER-regulated target genes. Motif finding was employed to analyze ER concordant transcription factors (TFs) in MCF7 cell. The Gene Ontology (GO) was used to conduct functional enrichment analysis. We identified 9,134 ER binding sites in E2 stimulation group and 1,969 in control group. GO enrichment analysis of target genes showed that ER-regulated target genes mainly participated in mRNA catabolic process, protein complex disassembly, and protein localization to organelle-related biology process; while in E2 stimulation group, the function of ER-regulated target genes sharply changed. The effect of E2 in MCF7 cell suggested that activated ER probably reacted with several TFs and then co-regulated related genes expression. Furthermore, several TFs, such as PAX6, SMAD3, and ESR2, had multiply cellular regulation function. Our results showed that E2 stimulates breast cancer cell growth through ER. This may infer the function of ER in occurrence and development of breast cancer. Together, our study would pave ways for discussing ER concordant TFs and studying other ER-recruited TFs.
KeywordsBreast cancer Estrogen receptor Estradiol stimulation ChIP-seq
This work was supported by grant PKJ2012-Y11 from the Science and Technology Development Foundation from Pudong New District, Shanghai, People’s Republic of China and by grant PWRq2011-16 from the Outstanding Young Foundation from Pudong New District, Shanghai, People’s Republic of China.
- 8.Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, et al. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res. 1999;55:163–93. discussion 94–5.Google Scholar
- 9.Grober OM, Mutarelli M, Giurato G, Ravo M, Cicatiello L, De Filippo MR, et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics. 2011;12(1):36.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Johnson KN, Zaveri N, Gupta K. Interaction of naloxone and estrogen receptor in breast cancer. Morphine and Metastasis. Springer; 2013. p. 15–29.Google Scholar
- 16.Routh A, Johnson JE. Discovery of functional genomic motifs in viruses with ViReMa–a Virus Recombination Mapper–for analysis of next-generation sequencing data. Nucleic Acids Res. 2013; gkt916.Google Scholar
- 30.Zong XY, Yu Y, Ling ZQ, Meng XL. Possible role of Pax-6 in promoting breast cancer cell proliferation and tumorigenesis. Biochem Mol Biol Rep. 2011;44(9):595–600.Google Scholar